<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77112">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01746745</url>
  </required_header>
  <id_info>
    <org_study_id>14892</org_study_id>
    <secondary_id>I4J-MC-HHBF</secondary_id>
    <nct_id>NCT01746745</nct_id>
  </id_info>
  <brief_title>A Study of LY2940680 in Healthy Participants</brief_title>
  <official_title>Disposition of [14C]-LY2940680 Following Oral Administration in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single dose study of radiolabelled LY2940680 taken by mouth in healthy
      participants to study how the body absorbs and removes LY2940680 from the blood.  This study
      is for research purposes only and is not intended to treat any medical condition.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose up to 14 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Predose up to 14 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of LY2940680 and Radioactivity Maximum Observed Concentration (Cmax)</measure>
    <time_frame>Predose up to 14 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of LY2940680 and Radioactivity Time of Maximum Observed Concentration (Tmax)</measure>
    <time_frame>Predose up to 14 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Pharmacokinetics of LY2940680 and Radioactivity Area Under the Concentration-Time Curve from Time Zero to the Last Timepoint with a Measurable Concentration (AUC 0 to tlast)</measure>
    <time_frame>Predose up to 14 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Urine</measure>
    <time_frame>Predose up to 14 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Plasma</measure>
    <time_frame>Predose up to 14 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Feces</measure>
    <time_frame>Predose up to 14 days postdose</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>[C14]-LY2940680</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single 100 mg of LY2940680 containing 100 micro curies of radioactivity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[C14]-LY2940680</intervention_name>
    <description>Administered as solution by mouth</description>
    <arm_group_label>[C14]-LY2940680</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Generally healthy sterile males or surgically sterile females or postmenopausal
             females, as determined by medical history and laboratory assessments

          -  Have a body mass index (BMI) of 18.5 to 32.0 kilograms per meter squared (kg/m^2),
             inclusive

        Exclusion Criteria:

          -  Regularly use known drugs of abuse and/or show positive findings on urinary drug
             screening

          -  Have consumed herbal supplements, grapefruit juice, grapefruits, grapefruit
             containing products, Seville orange juice, Seville oranges, star fruit, or star fruit
             juice within 7 days prior to dosing or intend to consume during the study have
             donated blood of more than 500 milliliters (mL) within the last month

          -  Have participated in a [14C]-study within the last 6 months prior to admission for
             this study

          -  Exposure to significant radiation within 12 months prior to dose (for example, serial
             X-ray or computed tomography scans, barium meal, current employment in a job
             requiring radiation exposure monitoring)

          -  Have a pattern less than once per 2 days to expel feces from the bowel through the
             rectum or acute constipation within 3 weeks of the day prior to dose
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 14, 2013</lastchanged_date>
  <firstreceived_date>December 7, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
